KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Treasury Shares (2018 - 2025)

Amneal Pharmaceuticals has reported Treasury Shares over the past 7 years, most recently at $2.2 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 87.36% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, down 87.36%, while the annual FY2025 figure was $2.2 million, 87.36% down from the prior year.
  • Treasury Shares for Q4 2025 was $2.2 million at Amneal Pharmaceuticals, down from $17.6 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $17.9 million in Q4 2022 and troughed at $2.2 million in Q4 2025.
  • A 4-year average of $13.8 million and a median of $17.5 million in 2023 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: grew 0.7% in 2024 and later plummeted 87.36% in 2025.
  • Year by year, Treasury Shares stood at $17.9 million in 2022, then fell by 2.64% to $17.5 million in 2023, then grew by 0.7% to $17.6 million in 2024, then plummeted by 87.36% to $2.2 million in 2025.
  • Business Quant data shows Treasury Shares for AMRX at $2.2 million in Q4 2025, $17.6 million in Q4 2024, and $17.5 million in Q4 2023.